FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Marc Barret

Research Profile

Anatomy

Chemicals & Drugs

Physiology

DNA Repair

Living Beings

Mouse

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Anna Kruczynski; Isabelle Vandenberghe; Arnaud Pillon; Sabrina Pesnel; Liliane Goetsch; Jean-Marc Barret; Yves Guminski; Alain Le Pape; Thierry Imbert; Christian Bailly; Nicolas Guilbaud
Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
Sonia Chelouah; Nicolas Guilbaud; Christian Bailly; Jean-Marc Barret; Caroline Monod-Wissler; Stéphane Vispé; Emmanuel Käs
An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
Jean-Philippe Annereau; V Brel; Charles Dumontet; Y Guminski; T Imbert; M Broussas; Stéphane Vispé; S Bréand; N Guilbaud; Jean-Marc Barret; C Bailly
A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Marc Barret (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Anna Kruczynski; Isabelle Vandenberghe; Arnaud Pillon; Sabrina Pesnel; Liliane Goetsch; Jean-Marc Barret; Yves Guminski; Alain Le Pape; Thierry Imbert; Christian Bailly; Nicolas Guilbaud
Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.
Investigational new drugs 2011;29(1):9-21.
2011: Sonia Chelouah; Nicolas Guilbaud; Christian Bailly; Jean-Marc Barret; Caroline Monod-Wissler; Stéphane Vispé; Emmanuel Käs
An integrated Drosophila model system reveals unique properties for F14512, a novel polyamine-containing anticancer drug that targets topoisomerase II.
PloS one 2011;6(8):e23597.
2010: Jean-Philippe Annereau; V Brel; Charles Dumontet; Y Guminski; T Imbert; M Broussas; Stéphane Vispé; S Bréand; N Guilbaud; Jean-Marc Barret; C Bailly
A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.
Leukemia research 2010;34(10):1383-9.
2009: Stéphane Vispé; Luc DeVries; Laurent Créancier; Jérome Besse; Sophie Bréand; David J Hobson; Jesper Q Svejstrup; Jean-Philippe Annereau; Didier Cussac; Charles Dumontet; Nicolas Guilbaud; Jean-Marc Barret; Christian Bailly
Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA.
Molecular cancer therapeutics 2009;8(10):2780-90.
2009: Anna Kruczynski; Patrice Mayer; Arnaud Marchand; Stéphane Vispé; Emmanuel Fournier; Jean-Philippe Annereau; Viviane Brel; Jean-Marc Barret; Georges Delsol; Thierry Imbert; Jacques Fahy; Christian Bailly
Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Anti-cancer drugs 2009;20(5):364-72.
2009: Yves Guminski; Martial Grousseaud; Sandrine Cugnasse; Viviane Brel; Jean-Philippe Annereau; Stéphane Vispé; Nicolas Guilbaud; Jean-Marc Barret; Christian Bailly; Thierry Imbert
Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system.
Bioorganic & medicinal chemistry letters 2009;19(9):2474-7.
2008: Jean-Marc Barret; Anna Kruczynski; Stéphane Vispé; Jean-Philippe Annereau; Viviane Brel; Yves Guminski; Jean-Guy Delcros; Amélie Lansiaux; Nicolas Guilbaud; Thierry Imbert; Christian Bailly
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Cancer research 2008;68(23):9845-53.
2008: Isabelle Vandenberghe; Laurent Créancier; Stéphane Vispé; Jean-Philippe Annereau; Jean-Marc Barret; Isabelle Pouny; Arnaud Samson; Yannick Aussagues; Georges Massiot; Frédéric Ausseil; Christian Bailly; Anna Kruczynski
Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.
Biochemical pharmacology 2008;76(4):453-62.
2008: Annie Pouilhès; Cyrille Kouklovsky; Yves Langlois; Jean-Pierre Baltaze; Stéphane Vispé; Jean-Philippe Annereau; Jean-Marc Barret; Anna Kruczynski; Christian Bailly
Synthesis and biological evaluation of bengacarboline derivatives.
Bioorganic & medicinal chemistry letters 2008;18(3):1212-6.
2007: S Vispé; I Vandenberghe; maxime Robin; J P Annereau; Laurent Créancier; V Pique; Jean-Pierre Galy; Anna Kruczynski; Jean-Marc Barret; C Bailly
Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Biochemical pharmacology 2007;73(12):1863-72.
2004: Christiane Santelli-Rouvier; Jean-Marc Barret; Christopher M Farrell; Derek Sharples; Bridget T Hill; Jacques Barbe
Synthesis of 9-acridinyl sulfur derivatives: sulfides, sulfoxides and sulfones. Comparison of their activity on tumour cells.
European journal of medicinal chemistry 2004;39(12):1029-38.
2004: Christian Bailly; Jean-Marc Barret; Anna Kruczynski
Antitumor pharmacology -- quo vadis?
Current medicinal chemistry. Anti-cancer agents 2004;4(5):389-91.
2004: Anna Kruczynski; Jean-Marc Barret; Benoît Van Hille; Nathalie Chansard; Jackie Astruc; Yoann Menon; Carole Duchier; Laurent Créancier; Bridget T Hill
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3156-68.
2003: Chantal Etiévant; Anna Kruczynski; Jean-Marc Barret; Dominique Perrin; Bridget T Hill
Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.
Biochemical pharmacology 2003;65(5):755-63.
2002: Christine Fabre; Jerzy Czaplicki; Michel Wright; Bridget Hill; Jean-Marc Barret; Jacques Fahy; Alain Milon
Differential binding to the alpha/beta-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses.
Biochemical pharmacology 2002;64(4):733-40.
2002: Jean-Marc Barret; Anna Kruczynski; Chantal Etiévant; Bridget T Hill
Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Cancer chemotherapy and pharmacology 2002;49(6):479-86.
2002: Jean-Marc Barret; Mathilde Cadou; Bridget T Hill
Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid.
Biochemical pharmacology 2002;63(2):251-8.
2002: Alain Duflos; Anna Kruczynski; Jean-Marc Barret
Novel aspects of natural and modified vinca alkaloids.
Current medicinal chemistry. Anti-cancer agents 2002;2(1):55-70.
2002: Jean-Marc Barret; Chantal Etiévant; Caroline Baudouin; Kirsten Skov; Marie Charvéron; Bridget T Hill
F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.
Anticancer research 2002;22(1A):187-92.
2001: Chantal Etiévant; Anna Kruczynski; Jean-Marc Barret; A S Tait; Maria Kavallaris; Bridget T Hill
Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro.
Cancer chemotherapy and pharmacology 2001;48(1):62-70.
2000: Jean-Marc Barret; Bridget T Hill; P L Olive
Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases.
British journal of cancer 2000;83(12):1740-6.
2000: Jean-Marc Barret; D Montaudon; Chantal Etiévant; Dominique Perrin; Anna Kruczynski; J Robert; Bridget T Hill
Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.
Anticancer research 2000;20(6B):4557-62.
2000: Benoît Van Hille; Chantal Etiévant; Jean-Marc Barret; Anna Kruczynski; Bridget T Hill
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
Anti-cancer drugs 2000;11(10):829-41.
2000: Dominique Perrin; Benoît Van Hille; Jean-Marc Barret; Anna Kruczynski; Chantal Etiévant; T Imbert; Bridget T Hill
F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Biochemical pharmacology 2000;59(7):807-19.
2000: Chantal Etiévant; Anna Kruczynski; Jean-Marc Barret; Dominique Perrin; Benoît Van Hille; Y Guminski; Bridget T Hill
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Cancer chemotherapy and pharmacology 2000;46(2):101-13.
2000: Jean-Marc Barret; Chantal Etiévant; Bridget T Hill
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Cancer chemotherapy and pharmacology 2000;45(6):471-6.
1999: C Jean-Decoster; L Brichese; Jean-Marc Barret; Y Tollon; Anna Kruczynski; Bridget T Hill; Michel Wright
Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Anti-cancer drugs 1999;10(6):537-43.
1999: Jean-Marc Barret; Chantal Etiévant; Jacques Fahy; J Lhomme; Bridget T Hill
Novel artificial endonucleases inhibit base excision repair and potentiate the cytotoxicity of DNA-damaging agents on L1210 cells.
Anti-cancer drugs 1999;10(1):55-65.
1998: Anna Kruczynski; Jean-Marc Barret; Chantal Etiévant; Francis Colpaert; Jacques Fahy; Bridget T Hill
Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Biochemical pharmacology 1998;55(5):635-48.
1998: Jean-Marc Barret; Bridget T Hill
DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets.
Anti-cancer drugs 1998;9(2):105-23.
1998: C Etievant; Jean-Marc Barret; Anna Kruczynski; Dominique Perrin; Bridget T Hill
Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Investigational new drugs 1998;16(1):3-17.
1997: Jean-Marc Barret; bernard salles; C Provot; Bridget T Hill
Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay.
Carcinogenesis 1997;18(12):2441-5.
1996: Jean-Marc Barret; Patrick Calsou; G Laurent; bernard salles
DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
Molecular pharmacology 1996;49(5):766-71.
1995: Jean-Marc Barret; Patrick Calsou; bernard salles
Deficient nucleotide excision repair activity in protein extracts from normal human lymphocytes.
Carcinogenesis 1995;16(7):1611-6.
1994: Jean-Marc Barret; Patrick Calsou; A K Larsen; bernard salles
A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
Molecular pharmacology 1994;46(3):431-6.
1994: E Levy; C Baroche; Jean-Marc Barret; Claire Alapetite; bernard salles; Dietrich Averbeck; Ethel Moustacchi
Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair.
Carcinogenesis 1994;15(5):845-50.
1994: A P Ernould; Gilles Ferry; Jean-Marc Barret; A Genton; Jean A Boutin
Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60.
International journal of peptide and protein research 1994;43(5):496-504.
1993: Jean-Marc Barret; A P Ernould; Gilles Ferry; A Genton; Jean A Boutin
Integrated system for the screening of the specificity of protein kinase inhibitors.
Biochemical pharmacology 1993;46(3):439-48.
1993: A P Ernould; Gilles Ferry; Jean-Marc Barret; A Genton; Jean A Boutin
Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60.
European journal of biochemistry / FEBS 1993;214(2):503-14.
1993: Patrick Calsou; Jean-Marc Barret; S Cros; bernard salles
DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin.
European journal of biochemistry / FEBS 1993;211(3):403-9.
1993: Jean-Marc Barret; A P Ernould; M H Rouillon; Gilles Ferry; A Genton; Jean A Boutin
Studies of the potency of protein kinase inhibitors on ATPase activities.
Chemico-biological interactions 1993;86(1):17-27.